Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma

Inclusion Criteria: * ≥ 18 years old * Refractory or relapsed indolent NHL. Eligible WHO histologies include follicular NHL (Grades 1, 2, and 3); marginal zone nodal; marginal zone splenic; and mucosa-associated lymphoid tissue (MALT) types * Failed ≥ 1 previous regimens, one of which must have contained rituximab as either a single agent or in combination with chemotherapy * ECOG performance status score either 0 or 1 * Willing and able to provide written informed consent Exclusion Criteria: Laboratory values of: * Platelet count \< 50,000/µL * AST or ALT \> 2 x the upper limit of normal (ULN) * Total bilirubin \> 2 x ULN * Creatinine \> 2.0 mg/dL and * Greater than three prior regimens (where a regimen is defined as a treatment for NHL given after disease progression) * Uncontrolled hypertension * Known history of porphyria, G6PD deficiency, HIV